Showing results (131-140 of 6,998) with videos related to

Sort By:
Pageof 700
Lung Cancer (Amsterdam, Netherlands)|March 3, 2020
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastasesGiulia Corrao, Giulia Marvaso, Roberto Ferrara, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2020
Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancerShawn J Rice, Xin Liu, Victoria Hyland, et al.
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greaterLongjiang She, Huabin Hu, Mengting Liao, et al.
Lung Cancer (Amsterdam, Netherlands)|October 5, 2020
Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLCGracy Crane, Vlatka Smoljanovic, Nasreen Khan, et al.
Lung Cancer (Amsterdam, Netherlands)|October 16, 2020
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patientsNicola Fusco, Valentina Vaira, Ilaria Righi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapyRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancerDavid E Kozono, Thomas E Stinchcombe, Joseph K Salama, et al.
Lung Cancer (Amsterdam, Netherlands)|June 15, 2021
Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohortMorten Borg, Sara W C Wen, Line Nederby, et al.
Lung Cancer (Amsterdam, Netherlands)|July 3, 2022
The impact of station 4L lymph node dissection on short-term and long-term outcomes in non-small cell lung cancerYang Wo, Hang Li, Yang Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Pageof 700